Halozyme Therapeutics Inc.

NASDAQ:HALO

54.00

+0.16 (+0.30%)

4:20:00 PM EDT: $54.00 0.00 (0.00%)

Market Cap (Intraday)	6.67B
Current PE	13.75
Forward PE	10.09
2yr Forward PE	7.54

See more stats

Estimates Current Quarter

Revenue	$282.6 Million
Adjusted EPS	$1.21

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Halozyme Therapeutics Inc. Stock, NASDAQ:HALO

12390 El Camino Real, San Diego, California 92130

United States of America

Phone: +1.858.794.8889

Number of Employees: 350

http://www.halozyme.com

Description

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.